Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

Shiba Teruo; Ishii So; Okamura Tomoo; Mitsuyoshi Rika; Pfarr Egon; Koiwai Kazuki

首页> 外文期刊>Diabetes research and clinical practice >Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

【24h】

Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

机译：Empagliflozin在日本患者2型糖尿病患者中的疗效和安全性：由三种临床试验的汇集数据的体重指数和年龄的分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Aims: To investigate the efficacy and safety of empagliflozin in subgroups based on body mass index (BMI) and age, using a pooled data set from Japanese patients with type 2 diabetes mellitus (T2DM).

机译：目的：利用来自日本患者2型糖尿病（T2DM）的汇总数据，探讨基于体重指数（BMI）和年龄的亚组中Empagliflozin的疗效和安全性。

著录项

来源
《Diabetes research and clinical practice》 |2017年第2017期|共10页
作者
Shiba Teruo; Ishii So; Okamura Tomoo; Mitsuyoshi Rika; Pfarr Egon; Koiwai Kazuki;
展开▼
作者单位

Toho Univ Ohashi Med Ctr Div Diabet &

Metab Meguro Ku 2-17-6 Ohashi Tokyo 1538515 Japan;

Eli Lilly Japan KK Minato Ku 4-15-1 Akasaka Tokyo 1070052 Japan;

Nippon Boehringer Ingelheim Co Ltd Shinagawa Ku 2-1-1 Osaki Tokyo 1416017 Japan;

Nippon Boehringer Ingelheim Co Ltd Shinagawa Ku 2-1-1 Osaki Tokyo 1416017 Japan;

Boehringer Ingelheim Pharma GmbH &

Co KG Ingelheim Germany;

Nippon Boehringer Ingelheim Co Ltd Shinagawa Ku 2-1-1 Osaki Tokyo 1416017 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
HbA1c; FPG; BMIl; Age; T2DM; Pooled analysis;

机译：HBA1C;FPG;BMIL;年龄;T2DM;汇总分析;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials [J] . Shiba Teruo, Ishii So, Okamura Tomoo, Diabetes research and clinical practice . 2017,第期

机译：Empagliflozin在日本患者2型糖尿病患者中的疗效和安全性：由三种临床试验的汇集数据的体重指数和年龄的分析
2. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type?2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type?2 Diabetic Patients: Long‐term Use study [J] . Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Journal of diabetes investigation. . 2019,第5期

机译：体重指数对日本2型糖尿病患者依普列净疗效和安全性的影响：依普列净治疗2型糖尿病患者指定药物使用结果调查的3个月中期结果的亚组分析：术语使用研究
3. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials [J] . Yoon Kun-Ho, Nishimura Rimei, Lee Jisoo, Diabetes, obesity & metabolism . 2016,第10期

机译：恩帕格列净对亚洲国家2型糖尿病患者的疗效和安全性：来自四项III期试验的汇总数据
4. Clinical observation of traditional Chinese Baduanjin Qigong (Eight trigrams boxing) in the treatment of patients with type 2 diabetes mellitus [C] . Yunchuan Wu, Feng Hao, Han Yang, International Conference on Information Technology in Medicine and Education . 2018

机译：中国传统的Baduanjin气功（八三胎拳）治疗2型糖尿病患者的临床观察
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Rationale and design of the EMPA-ELDERLY trial: a randomised double-blind placebo-controlled 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes [O] . Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, 2021

机译：Empa-Resion试验的理由和设计：随机双盲安慰剂控制52周的临床试验的钠葡萄糖Cotoransporter-2抑制剂Empagliflozin患者2型糖尿病患者的疗效和安全性
7. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials [O] . Sakai Soichi, Kaku Kohei, Seino Yutaka, 2016

机译：根据基线体重指数分层的日本2型糖尿病患者中SGLT2抑制剂Luseogliflozin的疗效和安全性：52周III期试验数据的汇总分析

Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅